Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.44 |
| ▸ | ANPEP | P15144 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668280 | 0.91 | MMP2 (0.43) | MMP2FKBP1AANPEPALDH1A1TSHR | |
| SCHEMBL16611573 | 0.87 | FKBP1A (0.41) | MMP2FKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL16611571 | 0.87 | FKBP1A (0.41) | MMP2FKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL10139494 | 0.86 | FKBP1A (0.43) | MMP2FKBP1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL16611802 | 0.86 | FKBP1A (0.41) | MMP2FKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL22543467 | 0.86 | KLK7 (0.46) | MMP2FKBP1AKMT2A | |
| SCHEMBL22543395 | 0.86 | KLK7 (0.46) | MMP2FKBP1AKMT2A | |
| Hydrochloric Acid SCHEMBL16611804 | 0.86 | FKBP1A (0.41) | MMP2FKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL22608698 | 0.85 | FKBP1A (0.43) | FKBP1A | |
| SCHEMBL31294399 | 0.83 | MMP2 (0.54) | MMP2FKBP1AANPEPACEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854786-B1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | UBE CORP (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12281074-B2 | Method for producing amino acid derivatives | UBE CORPORATION (JP) | 2025-04-22 | — | — | US | disclosed |
| US-12202800-B2 | Method for producing amino acid derivatives | API CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240150292-A1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | API CORPORATION (JP) | 2024-05-09 | — | — | US | disclosed |
| US-11897844-B2 | Method for producing amino acid derivatives | API CORPORATION (JP) | 2024-02-13 | — | — | US | disclosed |
| US-20240002340-A1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | API CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-112930338-A | Process for the preparation of amino acid derivatives | 株式会社API | 2021-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150292-A1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | PTGS2, PTGES, PTGS1 | MMP2 3356/4885FKBP1A 2960/4885ANPEP 500/4885 |
| US-12202800-B2 | Method for producing amino acid derivatives | GLO1, BCAT2, BCAT1 | MMP2 2853/4885FKBP1A 1159/4885ANPEP 144/4885 |
| US-20240002340-A1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | GLO1, BCAT2, BCAT1 | MMP2 2853/4885FKBP1A 1159/4885ANPEP 144/4885 |
| US-11897844-B2 | Method for producing amino acid derivatives | PTGS2, PTGES, PTGES2 | MMP2 3155/4885FKBP1A 3004/4885ANPEP 524/4885 |
| US-12281074-B2 | Method for producing amino acid derivatives | PTGS2, PTGES, PTGES2 | MMP2 3155/4885FKBP1A 3004/4885ANPEP 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.